The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) have awarded the 2023 ESCEO-IOF Pierre Meunier Young Scientist Award to Dr Germain Honvo, Lecturer of Epidemiology and Public Health at the University of Abomey-Calavi (Benin), and a Scientific Collaborator of the University of Liège (Belgium), Division of Public Health, Epidemiology and Health Economics. The Award was presented on May 6th, 2023 during a special session of the WCO-IOF-ESCEO 2023 in Barcelona, Spain.
The ESCEO-IOF Pierre Meunier Young Scientist Award has been awarded annually since 2017 to individual young investigators who have demonstrated outstanding scientific merit early in their careers, prior to reaching a prominent academic position, and who are expected to be future thought-leaders in the musculoskeletal field.
Professor Jean-Yves Reginster, ESCEO President and Co-Chair of WCO-IOF-ESCEO 2023 noted,
"It is a great pleasure to present this prestigious award to Dr Honvo. As a young investigator he has already made important international contributions, including as a clinical researcher in the field of osteoarthritis, and through his publications in guideline development and his contributions on behalf of the WHO within the field of Healthy Ageing. Already a respected academic reviewer and on the editorial board of several peer-reviewed journals, Dr Honvo is certainly on track to be a leading global expert in the field of pubic health and ageing research."
Dr Germain Honvo (MSc, PhD) is Epidemiologist and Public Health specialist, with a background in Biomedical Sciences (BSc). He is currently Lecturer of Epidemiology and Public Health at the University of Abomey-Calavi (Benin), and a Scientific Collaborator of the University of Liège (Belgium), at the Division of Public Health, Epidemiology and Health Economics. Dr Honvo is also Advisor to the World Health Organization (WHO) Collaborating Center for Epidemiology of Musculoskeletal Health and Ageing (University of Liège, Belgium). His research interest focuses on the epidemiology of musculoskeletal disorders and ageing. As a young researcher, he is the author of several scientific publications including systematic reviews and meta-analyses, as well as recommendations for clinical practice and clinical research in the field of osteoarthritis. He is currently actively working on a project on measures of locomotor capacity in older people, in the framework of the WHO Initiative on Measurement of Healthy Ageing.
Dr Honvo is a member of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). He is a Section Editor (Methodology) of Archives of Public Health, Academic Editor on the PLOS ONE Editorial Board, Review Editor on the Editorial Board of Frontiers in Medicine (Specialty section, Rheumatology), and Reviewer Board member of the Journal of Clinical Medicine and of Medicina.
Germain Honvo is currently a member of the Guideline Development Group (GDG) for the WHO Guideline on chronic primary low back pain in adults. He has contributed to the WHO Clinical Consortium on Healthy Ageing (CCHA) since 2020.
World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO Barcelona 2023)
Held jointly by IOF and ESCEO, the Congress took place in Barcelona, Spain from May 4-7, 2023. WCO-IOF-ESCEO is the world’s largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders, including sarcopenia and frailty. For complete information visit www.wco-iof-esceo.org #OsteoCongress
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. www.esceo.org @esceo
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as more than 315 patient, medical and research organizations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. www.osteoporosis.foundation @iofbonehealth